These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38722496)

  • 21. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
    Tan X; Liang Y; Gamble C; King A
    Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States.
    Dacosta Byfield SA; Adejoro O; Copher R; Chatterjee D; Joshi PR; Worden FP
    Adv Ther; 2019 Apr; 36(4):896-915. PubMed ID: 30820872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
    Varnado OJ; Vu M; Buysman EK; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    Curr Med Res Opin; 2024 Apr; 40(4):635-646. PubMed ID: 38334320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
    Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
    J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
    Brunton SA; Mosenzon O; Wright EE
    Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
    Ren H; Berry S; Malkin SJP; Hunt B; Bain S
    BMJ Open; 2023 Sep; 13(9):e070473. PubMed ID: 37775297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
    Yeaw J; Lee WC; Aagren M; Christensen T
    J Manag Care Pharm; 2012; 18(1):21-32. PubMed ID: 22235952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
    Jain AB; Reichert SM; Amadid H; Braae UC; Bradley RM; Kim JW; Soo V; Yale JF
    Diabetes Obes Metab; 2024 May; 26(5):1799-1807. PubMed ID: 38468125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
    Powell J; Piszczatoski C; Taylor JR
    Clin Ther; 2020 Oct; 42(10):2100-2116. PubMed ID: 32873415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
    Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
    JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings.
    Yamada H; Yoshida M; Funazaki S; Morimoto J; Tonezawa S; Takahashi A; Nagashima S; Masahiko K; Kiyoshi O; Hara K
    J Cardiovasc Dev Dis; 2023 Apr; 10(4):. PubMed ID: 37103055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment.
    Baldassarre MPA; Di Dalmazi G; Coluzzi S; Carrieri F; Febo F; Centorame G; Cassino P; Piacentino L; Baroni MG; Consoli A; Formoso G
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892765
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.
    Marques Vidas M; López-Sánchez P; Sánchez-Briales P; López Illazquez MV; Portolés J
    J Clin Med; 2024 Aug; 13(17):. PubMed ID: 39274378
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.
    Evans M; Husain M; Srivastava A; Mangla KK; Kuhlman AB; Lingvay I
    Adv Ther; 2024 May; 41(5):1843-1859. PubMed ID: 38340253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
    Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
    Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.